Last reviewed · How we verify
Hyperpolarized Pyruvate
At a glance
| Generic name | Hyperpolarized Pyruvate |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anosmia
- Dysgeusia
Key clinical trials
- Hyperpolarized Imaging in Diagnosing Participants With Glioma (PHASE1)
- Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma (PHASE1)
- Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors (PHASE2)
- Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain
- Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
- Hyperpolarized MRSI in Ischemic Heart Disease: A Metabolic Investigation of the Heart Muscle
- Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
- Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |